Oligonucleotide Synthesis Market

Danaher Corporation (US) and Thermo Fisher Scientific, Inc. (US) are Leading Players in the Oligonucleotide Synthesis Market

The global oligonucleotide synthesis market is projected to reach USD 14.1 billion by 2026 from USD 6.3 billion in 2021, at a CAGR of 17.6% during the forecast period. The major factors driving the growth of this market include the increasing use of synthesized oligos in therapeutic applications, increasing government funding, and the growing focus on personalized medicine.

Prominent players operating in the oligonucleotide synthesis market are Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), and Agilent Technologies, Inc. (US). The prominent players in the oligonucleotide therapeutics market are Biogen Inc. (US) and Sarepta Therapeutics, Inc. (US).

To know about the assumptions considered for the study download the pdf brochure

DANAHER CORPORATION (US)

Danaher is one of the key players in the oligonucleotide synthesis market, owing to its robust product portfolio and brand recognition. The two largest acquisitions of IDT (US) and Cytiva (US) enhanced Danaher’s oligonucleotide product offering. The company now offers synthesized oligos such as primers & probes and the raw materials used to synthesize oligos such as reagents and equipment. Danaher’s key growth strategy is introducing active product launches. For instance, in 2019, the company launched the longest (up to 350 mers in length), high quality, and ready-to-use custom oligo pools in the market. Such strategic developments help the company sustain its position in the oligonucleotide synthesis market.

THERMO FISHER SCIENTIFIC, INC. (US)

Thermo Fisher Scientific (US) led the oligonucleotide synthesis market with a share of 21.4% in 2020. The company has an exhaustive product portfolio consisting of primers, probes, custom oligos, phosphoramidites, reagents, and custom oligo modification. It has adopted various organic and inorganic growth strategies to strengthen its market position. For instance, in 2019, Thermo Fisher supported BioNTechs (Germany) messenger RNA (mRNA) manufacturing platform by supplying nucleotides, enzymes, reagents, and other critical raw materials to expand their manufacturing capacities. Despite the pandemic, the company witnessed a substantial increase in the revenue of its Life Sciences segment as compared to 2019. Increasing revenues in the company’s business were primarily driven by the demand for COVID-19 testing with higher sales of bioproduction products and genetic sciences, which include oligonucleotide products.

BIOGEN, INC. (US)

Biogen led the oligonucleotide synthesis therapeutics market with a share of 59.3% in 2020. This large share can be attributed to the launch of SPINRAZA in 2016. SPINRAZA is the first and only approved treatment for SMA (Spinal Muscular Atrophy). Globally, SPINRAZA’s revenue reached USD 2 billion in 2020. In 2019, SPINRAZA (nusinersen) was approved by the China National Medical Products Association (NMPA) for the treatment of 5q spinal muscular atrophy (SMA), thus expanding the company’s presence in China. The company has its oligonucleotide synthesis manufacturing (OSM) facility in North Carolina, which is utilized for manufacturing antisense oligonucleotide drugs like SPINRAZA and other antisense oligonucleotide drug candidates, which are currently in the pipeline.

SAREPTA THERAPEUTICS, INC. (US)

Sarepta Therapeutics accounted for the second-largest share of 13.2% of the oligonucleotide therapeutics market in 2020. This can be attributed to its commercial launch of EXONDYS 51 in the US in September 2016. In the US, EXONDYS 51 is the first disease-modifying therapy to receive accelerated approval for the treatment of Duchenne Muscular Dystrophy (DMD). The company is pursuing a broad coverage of EXONDYS 51 by executing strategic initiatives designed to achieve successful commercialization of EXONDYS 51. In the last three years, the company also received US FDA approvals of two new oligonucleotide-based drugs, namely, VYONDYS 53 and AMONDYS 45, for the treatment of DMD. The company has multiple drugs in clinical trials that are expected to be marketed in the coming years.

Related Reports:

Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, siRNA), Research (PCR), Diagnostic), End User (Hospital, Pharma, CROs) - Global Forecast to 2026

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Report Code
BT 2680
RI Published ON
4/9/2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Oligonucleotide Synthesis Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved